Compare Davita Inc (DVA) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Davita Inc trades at $178.19 (market cap $11.38B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.92. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | QQQE | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $122.72 |
52-Week Low | $103.87 | $96.06 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $123.01, up 0.7% today, with a bullish technical signal from moving averages. The fund provides diversified exposure to the Nasdaq-100 with equal weighting, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a defensive play amid tech-led market rallies and the upcoming inclusion of SpaceX in the index.
The outlook remains positive given equal-weight diversification benefits and strong Nasdaq-100 growth trends. Key risks include market volatility and sector concentration, but analyst sentiment favors QQQE for balanced Nasdaq exposure. The ETF's structure mitigates single-stock risk while capturing broad large-cap growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
